DOI: 10.7860/JCDR/2024/69801.19460

Internal Medicine Section

Diagnostic Accuracy of Cerebrospinal Fluid Procalcitonin and Serum Procalcitonin in Adult Patients with Bacterial Meningitis: A Cross-sectional Study

MONICA KARAN¹, APARAJITA PRIYADARSHINI², KAVITA AGGARWAL³, KRISHNA PADARABINDA TRIPATHY⁴, PRADIP KUMAR BEHERA⁵



ABSTRACT

Introduction: Bacterial Meningitis (BM) is a serious health problem worldwide with high mortality and permanent long-term neurological sequelae. Cerebrospinal Fluid (CSF) analysis is the cornerstone for diagnosing BM, but the lack of specificity creates a difficult clinical scenario for initiating proper treatment. Empiric antibiotic use in patients with suspected meningitis at primary care settings decreases the yield of CSF culture and alters CSF cytological and biochemical findings, making it further difficult to diagnose BM. To overcome this difficulty, there is a need for other biochemical markers with higher sensitivity and specificity.

Aim: To determine the diagnostic sensitivity and specificity of Procalcitonin (PCT) in serum and CSF in patients with BM and compare its diagnostic accuracy in both sample types.

Materials and Methods: A cross-sectional study was conducted in the Department of Internal Medicine at a tertiary care centre

in eastern India from September 2018 to August 2020. A total of 82 adult patients with meningitis were recruited as per the protocol, and CSF analysis was done along with estimation of PCT in serum and CSF. Receiver Operating Characteristics (ROC) curve analysis of serum and CSF PCT was used to determine sensitivity and specificity with a 95% confidence interval

Results: Out of the 82 patients recruited, 30 (36.6%) had BM. CSF PCT with a cut-off value of >0.45 ng/mL had a sensitivity of 86.7% and specificity of 92.3%. The sensitivity of serum PCT with a cut-off value of >0.6 ng/mL was 83.3%, and specificity was 86.5%. There was no statistically significant difference in sensitivity and specificity between CSF and serum PCT in patients with BM (p-value=0.7988).

Conclusion: Both serum and CSF PCT were found to have high sensitivity and specificity as markers for diagnosing BM without any statistically significant difference between them.

Keywords: Biomarker, Diagnostic sensitivity, Diagnostic specificity, Meningoencephalitis, Pyogenic meningitis

INTRODUCTION

The occurrence of BM is a significant health problem worldwide, especially in developing countries, with high morbidity and mortality even after significant development in antibiotics and vaccines [1]. Mortality rates due to BM ranges from 10 to 20% in developed nations and can reach as high as 50% in developing countries with lower resources, where BM stands as the fourth leading cause of disability [2]. Differentiating BM clinically from viral, tubercular, or fungal meningitis is difficult but as all these conditions require different but urgent therapeutic decisions, the early and accurate diagnosis of BM is crucial to save patients [3]. The diagnosis of BM largely depends on the microbiological, cytological, and biochemical analysis of CSF [4]. Though bacterial culture and gram staining of CSF are highly specific for diagnosing BM, the accuracy rates are around 70-90% for culture and 50-90% for gram staining in untreated patients. Cases admitted to tertiary care centres are often transferred from peripheral hospitals where they may have already received antibiotics, leading to further reduced diagnostic yields from CSF gram staining or culture [5,6]. CSF cytology and biochemical analysis for leukocyte type and count, of leukocytes and CSF protein levels, serve as alternative methods for diagnosing BM, but their sensitivity and specificity are relatively low [7]. Therefore, in tertiary care settings, there is a necessity for additional biochemical markers with high sensitivity and specificity that are not influenced by prior antibiotic use.

PCT has been considered as a marker of bacterial infection due to substantial rise of serum level of PCT (as high as 1000-fold rise)

in response to exposure to bacterial Lipopolysaccharide (LPS) [8]. Elevated serum PCT levels in bacterial infections have been documented in number of researches [9-12]. Serum PCT is now routinely being used in clinical settings as a marker for bacterial infections, including BM [13-15]. The diagnostic efficacy of CSF PCT in central nervous system infections like meningitis is still being evaluated, with conflicting results. Studies by Mills GD et al., Jereb M et al., and Alkholi UM et al., have reported elevated levels of PCT in CSF in cases of BM [16-18]. Ahmad M et al., also observed a similar elevation of CSF PCT in BM cases, demonstrating high diagnostic value (sensitivity 100% and specificity 96.43%) [19]. However, some researchers have reported contradictory observations. Shimetani N et al., observed no significant difference in CSF PCT levels between patients with meningitis and those with non inflammatory central nervous system diseases [20].

In another study in paediatric subjects, the CSF PCT was undetectable in both bacterial as well as viral meningitis [21]. Although many studies have been carried out, the diagnostic accuracy of CSF PCT in bacterial meningitis has not been confirmed, and the role of CSF PCT as a diagnostic marker of bacterial meningitis is yet to be established. In this study, authors investigated the CSF as well as serum PCT levels in cases of meningitis with an aim to prove whether PCT can be used as a marker in diagnosing BM and differentiating it from other non BM. The two biomarkers were compared in cases of BM to determine which one (CSF or serum PCT) has superior diagnostic accuracy.

MATERIALS AND METHODS

The present study, a hospital-based cross-sectional study, was carried out in the Department of Internal Medicine, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India, from September 2018 to August 2020. The study protocol was approved by the Institutional Research as well as the Ethics Committee (Ref. no. KIMS/KIIT/IEC/134/2018).

Inclusion criteria: Adult patients aged 18 years or more admitted with a clinical diagnosis of meningitis and presence of at least two of the following clinical presentations: fever, headache, neck stiffness, mental symptoms, impaired consciousness, or seizure was minimum clinical criteria required for clinical diagnosis of meningitis [22] and were included in the study.

Exclusion criteria: Patients with contraindications to lumbar puncture, presence of any active malignancy, intracranial space-occupying lesions, immunocompromised status, or Chronic Kidney Disease (CKD) were excluded from the study. Cases with CSF findings not consistent with bacterial, tubercular, or viral meningitis were also excluded.

Sample size calculation: The sample size was calculated using the minimum sample size determination procedure for estimating a population proportion. The formula used for the purpose was as follows:

$$n = (z_{1-\alpha/2}^2 P(1-P)/d^2)$$

Where n=Minimum sample size.

 $z_{1-\alpha/2}^2$ =value of the standard normal variant for $1-\alpha/2$ level of significance=1.96.

P=Anticipated population proportion.

Confidence level=1-∞=95%

Anticipated population proportion P=80% [23,24].

Margin of error d=0.09 (8% point).

Design effect=1 (Simple random sample).

Given these input values, the minimum sample size required was computed as 76. However, the final sample size was taken as 82.

After exercising the inclusion and exclusion criteria and receipt of signed informed consent from the patients or their legitimate guardians in cases of altered mental status, the subjects were enrolled in the study.

A thorough clinical history and detailed clinical examination findings were recorded in the predesigned case report form. Routine laboratory tests were done in all enrolled cases, and lumbar puncture was performed according to the protocol. CSF was studied for cell count, cell type, biochemical analysis, Gram staining and culture, Ziehl-Neelsen (ZN) staining, Cartridge-Based Nucleic Acid Amplification Test (CBNAT), Adenosine Deaminase (ADA), Polymerase Chain Reaction (PCR) for viral aetiologies, India ink, and CSF Procalcitonin (PCT) estimation. A blood sample for serum PCT was also simultaneously sent.

PCT levels in CSF and serum samples was estimated by I CHROMATM II PCT analyser (BodiTech Med Inc, South Korea), which employs a sandwich immunodetection method. The test results were expressed in ng/mL with a reference range of 0.5 ng/mL and a working range of 0.1-100 ng/mL.

According to the patients' clinical presentation and CSF analysis, patients were classified according to the aetiology of meningitis as BM, viral meningitis, or tubercular meningitis.

A diagnosis of BM was established based on CSF analysis meeting any of the following criteria:

- CSF cytological analysis-cell count over 500/mm³ with neutrophilic predominance.
- ii. Positive CSF culture or

iii. Negative culture but positive Gram stain [25,26].

Similarly, a diagnosis of viral meningitis was made based on CSF analysis meeting any of the following criteria:

- i. CSF cytological analysis-cell count (25-500/μL) with pleocytosis or.
- ii. Positive PCR results for any viral DNA/RNA in CSF [26,27].

A diagnosis of tubercular meningitis was made based on CSF analysis meeting any of the following criteria:

- i. Positive smear microscopy for acid-fast bacilli.
- ii. Positive ADA or CBNAAT positive.
- iii. Lymphocytic pleocytosis (cell count 10-500 cells/μL) with elevated protein (1-5g/L) [28].

After patients were classified into three groups according to the diagnostic criteria, the epidemiological data, clinical characteristics, cytological and biochemical parameters of CSF were analysed among patients with BM and other types of meningitis. The PCT levels in CSF and serum in patients with BM were analysed for any statistical significance and for diagnostic sensitivity and specificity. The sensitivity and specificity of CSF and serum PCT in cases of BM were compared for any statistically significant difference.

STATISTICAL ANALYSIS

The collected data were scrutinised, coded, and analysed by IBM Statistical Package for Social Sciences (SPSS) version 24.0 statistical software, SPSS South Asia Pvt., Ltd. Categorical variables were studied by frequency procedure. The association of seizures and co-morbidities with the type of meningitis was assessed using the cross-tabulation procedure and the Chi-square test of independence. Comparison of CSF parameters like glucose, protein, and ADA with the type of meningitis, and duration of hospital stay with the type of meningitis were done by using one-way Analysis of Variance (ANOVA) analysis. ROC curve analysis was conducted to evaluate the diagnostic accuracy of CSF PCT and serum PCT as markers of BM with a significance level for testing the hypothesis set at <0.05.

RESULTS

A total of 82 cases of meningitis diagnosed based on CSF criteria were included in the study, with a mean age of 49.0±17.6 years. The demographic and clinical characteristics of the study population are presented in [Table/Fig-1]. According to the diagnostic criteria used in the protocol, viral meningitis was the most common type, Upon analysing the incidence of BM in relation to seasonal variation, it was observed that most BM cases (14, 46.6%) were detected in the last quarter of the year (early winter).

The clinical, CSF, and serum characteristics of different types of meningitis have been presented in [Table/Fig-2]. Analysis of PCT levels in CSF in relation to different types of meningitis revealed that both CSF and serum PCT were significantly higher in BM compared to TB meningitis or viral meningitis. The association of co-morbidities and seizures with the type of meningitis is presented in [Table/Fig-3], indicating a higher incidence of seizures with BM.

To assess the efficacy of CSF and serum PCT in diagnosing BM, the 82 subjects in the study were divided into two groups: BM and Non BM, and ROC analysis was performed. The ROC analysis of CSF PCT is shown in [Table/Fig-4]. CSF PCT had a cut-off value of >0.45 ng/mL with an Area Under Curve (AUC) of 0.906 (p-value>0.0001), indicating that CSF PCT is a very good marker of BM at this cut-off value. The ROC analysis of serum PCT as a marker of BM is presented in [Table/Fig-5]. serum PCT had a cut-off value of >0.6 ng/mL with an AUC of 0.900 (p-value>0.0001), suggesting that serum PCT is also a very good marker of BM at this cut-off value. The sensitivity and specificity of CSF and serum PCT are shown in [Table/Fig-6].

Demographic/Clinical charact	n (%)	
Gender	Male	47 (57.3)
	Female	35 (42.7)
Age (years)	<50	40 (48.8)
	>50	42 (51.2)
	Bacterial	30 (36.6)
Types of meningitis	Viral	34 (41.4)
	Tubercular	18 (22)
	Fever	80 (97.6)
	Vomiting	78 (95.1)
Symptoms/signs	Headache	76 (92.7)
Symptoms/signs	Altered sensorium	8 (9.8)
	Seizure	17 (20.7)
	Neck stiffness	45 (54.9)
CSF findings (positiveness)	Gram staining	23 (28)
	CSF culture	20 (24.4)
	AFB staining	11 (13.4)
	CBNAT	13 (15.9)
Quarter wise Incidence of Bacterial Meningitis (BM) (n=30)	1st Quarter (Jan-March)	9 (30)
	2 nd Quarter (April-June)	5 (17)
	3rd Quarter (July-Sept)	2 (6.4)
	4th Quarter (Oct-Dec)	14 (46.6)

[Table/Fig-1]: Demographic and clinical characteristics of study participants (n=82). CSF:Cerebrospinal fluid;AFB:Acid fast bacilli;CBNAT:Cartridge-based nucleic acid amplification test

Bacterial meningitis (BM) (n=30)	Viral meningitis (n=34)	Tubercular meningitis (n=18)	p-value
40.6±16.6	55.9±16.6	49.9±15.8	0.002
10.2±3.1	6.0±1.3	7.8±1.8	<0.001
260.4±123.5	133.9±112.6	229.1±73.7	<0.001
30.9±9.4	52.2±20.6	36.9±7.0	<0.001
2.6±1.9	3.2±3.1	15.4±5.5	<0.001
3.9±4.3	0.64±1.36	0.49±0.19	<0.001
2.3±2.9	0.40±0.69	0.19±0.06	<0.001
15243.3±2259	6247.06±4191	5001.1±2760	<0.001
	meningitis (BM) (n=30) 40.6±16.6 10.2±3.1 260.4±123.5 30.9±9.4 2.6±1.9 3.9±4.3 2.3±2.9 15243.3±2259	meningitis (BM) (n=30) meningitis (n=34) 40.6±16.6 55.9±16.6 10.2±3.1 6.0±1.3 260.4±123.5 133.9±112.6 30.9±9.4 52.2±20.6 2.6±1.9 3.2±3.1 3.9±4.3 0.64±1.36 2.3±2.9 0.40±0.69 15243.3±2259 6247.06±4191	meningitis (BM) (n=30) meningitis (n=34) meningitis (n=18) 40.6±16.6 55.9±16.6 49.9±15.8 10.2±3.1 6.0±1.3 7.8±1.8 260.4±123.5 133.9±112.6 229.1±73.7 30.9±9.4 52.2±20.6 36.9±7.0 2.6±1.9 3.2±3.1 15.4±5.5 3.9±4.3 0.64±1.36 0.49±0.19 2.3±2.9 0.40±0.69 0.19±0.06

[Table/Fig-2]: Clinical, CSF and serum characteristics with different types of Meningitis (n=82).


Clinical characteristics	Bacterial meningitis (BM) (n=30)	Viral meningitis (n=34)	Tubercular meningitis (n=18)	p-value	
Co-morbidities in %	12 (40)	11 (32.4)	3 (16.7)	0.336	
No co-morbidity in %	18 (60)	23 (67.6)	15 (83.3)	0.336	
Seizure frequency in %	10 (33.3)	2 (5.9)	5 (27.8)	0.018	

[Table/Fig-3]: Association of comorbidity and seizure with type of meningitis.

When comparing CSF and serum PCT in patients with BM, it was found that CSF PCT had slightly higher sensitivity compared to serum PCT, but the difference was not statistically significant [Table/Fig-7].

DISCUSSION

Meningitis is a devastating disease with high mortality, and survivors also suffer from significant long-term sequelae with a detrimental



Serum Procalcitonin

100

80

40

AUC = 0.900
p-value<0.001

100-Specificity

[Table/Fig-5]: Showing the ROC analysis of Serum Procalcitonin (PCT).

	CSF PCT (n=30)	Serum PCT (n=30)
Area Under Curve (AUC)	0.906	0.900
95% Confidence interval	0.821 to 0.959	0.813 to 0.955
Significance level P (Area= 0.5)	<0.0001	<0.0001
Associated Criterion	>0.45	>0.6
Sensitivity (95% CI)	86.7	83.3
Specificity (95% CI)	92.3	86.5
[Table/Fig-6]: ROC analysis of CSF and serum PCT by in BM (n=30).		

CSF Procalcitonin (PCT) VS Serum Procalcitonin (PCT)		
0.00609		
0.0239		
-0.0407 to 0.0529		
0.255		
p-value=0.7988		

[Table/Fig-7]: Pair wise comparison of ROC curves of CSF and serum PCT in cases of Bacterial Meningitis (BM) (n=30).

impact on their quality of life [29]. As a disease, meningitis is a global public health challenge, and outbreaks of meningitis warrant urgent

attention. Though many different pathogens, including bacteria, mycobacteria, viruses, or fungi, can cause meningitis, bacteria are responsible for the highest burden of acute meningitis worldwide [30]. Due to similar symptoms and signs, clinicians mostly rely on CSF cytological and biochemical findings, which are neither too sensitive nor specific and leave the treating physician in a dilemma. CSF gram stain and culture are the gold standard, and although the sensitivity and specificity have increased in recent times due to newer techniques in microbiology labs, the culture positivity is still low in meningitis. In such scenarios, elevated serum PCT has been used as a surrogate marker of BM [31]. However, CSF PCT, although studied by some researchers [32,33], is still not in clinical use due to a lack of sufficient data, the rise of PCT in some non infectious conditions like increasing age or age-related degenerative neurological conditions [34,35], and the lack of standardised cut-off levels for CSF PCT in large studies. Additionally, there are only a few studies comparing head-to-head the diagnostic accuracy of CSF and serum PCT in cases of BM [27,35]. In this study, authors have attempted to determine the sensitivity and specificity of both CSF and serum PCT for the diagnosis of BM and have also compared their diagnostic accuracy.

In the present study, serum PCT was significantly higher in patients with BM compared to viral or tubercular meningitis (p-value <0.001). A similar observation was also noted by Shen HY et al., and Saproo N and Singh R [35,36]. Konstantinidis T et al., in their study, observed that CSF PCT levels in BM were significantly higher compared to viral meningitis and control groups with sensitivity of 100% and specificity of 96.43% [37]. Shen HY et al., in their study, also noted that both CSF and serum PCT were high in BM than the Non BM group [35]. Li Y et al., in their study on postneurosurgical BM, observed CSF PCT being high in BM patients with sensitivity and specificity of 68% and 72.7% [38]. In this study,

Shen HY et al., concluded that serum PCT was superior to CSF PCT and could be a reliable marker to differentiate BM from viral meningitis [35]. They also observed a positive correlation between serum and CSF PCT, and as the serum PCT was higher than CSF PCT, they opined that because of a breach in the blood-brain barrier in meningitis, the serum PCT has entered into the CSF with a resultant rise in CSF PCT. However, Li W et al., in their study found that CSF PCT was the only marker that was not affected by pretreatment with antibiotics in their patients and was a superior biomarker in terms of diagnostic accuracy, whereas serum PCT was low and failed as a biomarker [27]. The authors explained this finding in terms of non entry of antibiotics into CSF due to an intact blood-brain barrier. In this study, authors also observed a higher PCT level in CSF compared to serum in cases of BM, as most of the patients are referred from peripheral health facilities where they receive at least some antibiotics, including 3rd generation cephalosporins. Another explanation for high CSF PCT compared to serum may be the local production of PCT in the CSF, as the inflammation is focal and restricted to the subarachnoid space.

But in contrast to the observations of Li W et al., present study observed serum PCT to be a good marker of BM with sensitivity and specificity of 83.3% (95% CI) and 86.5% (95% CI). When CSF PCT and serum PCT were compared, there was no statistically significant difference between the two in terms of superiority as biomarkers (p-value=0.7988) [27]. Present study observation was against the findings of Shen HY et al., who, by ROC curve analysis, compared the diagnostic accuracy of serum and CSF PCT and observed a higher AUC for serum PCT and concluded that serum PCT is superior to CSF PCT as a diagnostic marker [35]. Similar studies from the literature have been compared in [Table/Fig-8] [27,35-38].

Authors name and year	Place of study	Number of subjects	Parameters assessed	Conclusion
Konstantinidis T et al., 2015 [37]	Greece	58	CSF Procalcitonin (PCT)	CSF PCT significantly higher in BM as compared to controls.
Li Y et al., 2015 [38]	Beijing, China	178	CSF PCT and Lactate	CSF PCT higher in BM patients as compared to non BM patients (p-value<0.001)
Shen HY et al., 2015 [35]	Shanghai, China	150	Serum and CSF PCT	Both CSF and serum PCT significantly elevated in BM than non BM patients
Li W et al., 2017 [27]	Xian, China	135	CSF and Serum PCT	CSF PCT was significantly higher in BM patients where as serum PCT elevation was not statistically significant.
Saproo N and Singh R 2021 [36]	Jammu, India	100	CSF and Serum PCT	Serum PCT elevated significantly but not CSF PCT in BM patients as compared to non BM patients
Present study, 2024	Bhubaneswar, India	82	CSF and Serum PCT	Both CSF and serum PCT significantly elevated in BM than non BM patients

[Table/Fig-8]: Comparison of similar studies in respect to conclusion [27,35-38]

similar observation were observed with both CSF and serum PCT being significantly higher in BM than in viral or tubercular meningitis patients with very high sensitivity and specificity (86.7% and 92.3%, respectively).

Li W et al., in their study, observed the median CSF PCT value in BM patients to be 0.22 (0.13-0.54) ng/mL, and with a cut-off value of 0.15 ng/mL, the sensitivity was 69.39 (95% CI) and specificity 91.49 (95% CI) [27]. In a meta-analysis by Kim H et al., the subgroup analysis regarding the cut-off value of CSF PCT among various studies, half of the included studies (n=9) had considered a CSF cut-off value of <0.5 ng/mL, and in the rest half of the studies, the cut-off was >0.5 ng/mL [39]. In the present study, the CSF PCT cut-off has been found to be >0.45 ng/mL with a sensitivity of 86.7 with 95% CI and specificity of 92.3 with 95%CI. The pooled sensitivity and specificity with a cut-off level <0.5 ng/mL was 0.899 (95% CI) and 0.844 (95% CI) [39], which was similar to the findings in the present study.

CSF PCT has been compared with serum PCT by some studies, with results showing disagreements among researchers. In their study to assess the diagnostic accuracy of CSF and serum PCT,

Limitation(s)

Though the subjects in the present study were mostly referred cases having received antibiotics before they were enrolled, and the subjects were not segregated as with or without antibiotic treatment, which may influence the PCT level in serum or CSF. A study with similar objectives but in groups with antibiotic and no antibiotic use will shed light on the influence of pretreatment antibiotics on serum and CSF PCT. The combined diagnostic accuracy of CSF PCT and other CSF parameters markers needs to be evaluated.

CONCLUSION(S)

From the present work, it can be concluded that both CSF and serum PCT can be good biomarkers in the diagnosis of BM and will help clinicians in differentiating bacterial from non BM. When questioning about superiority among the two, both CSF and serum PCT were of equal sensitivity and specificity for diagnosing BM in adult patients without any statistical significance.

Acknowledgement

Authors acknowledge the doctors in the treating team, residents of

the Department of Medicine, all the Technicians of the central Lab, KIMS for their valuable contribution towards this study.

REFERENCES

- [1] Zunt JR, Kassebaum NJ, Blake N. Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(12):1061-82.
- [2] Ettekoven CN, Beek DV, Brouwer MC. Update on community-acquired bacterial meningitis: Guidance and challenges. Clin Microbiol Infect. 2017;23(9):601-06.
- [3] Brouwer M, Thwaites G, Tunkel A, van de Beek D. Dilemmas in the diagnosis of acute community-acquired bacterial meningitis. Lancet. 2012;380(9854):1684-92. Doi: 10.1016/S0140-6736(12)61185-4.
- [4] Fouad R, Khairy M, Fathalah W, Gad T, El-Kholy B, Yosry A. Role of clinical presentations and routine CSF analysis in the rapid diagnosis of acute bacterial meningitis in cases of negative gram stained smears. J Trop Med. 2014;2014;213762.
- [5] Brizzi K, Hines EM, Mcgowin KL, Shah SS. Diagnostic accuracy of cerebrospinal fluid gram stain in children with suspected bacterial meningitis. Pediatr Infect Dis J. 2012;31(2):195-97.
- [6] Nigrovic LE, Malley R, Macias CG, Kanegaye JT, Moro-Sutherland DM, Schremmer RD, et al. Effect of antibiotic pretreatment on cerebrospinal fluid profiles of children with bacterial meningitis. Paediatrics. 2008;122(4):726-30.
- [7] Wu HM, Cordeiro SM, Harcourt BH, Carvalho MGS, Azwvido J, Oliveria TQ, et al. Accuracy of real-time PCR, Gram stain and culture for Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae meningitis diagnosis. BMC Infect Dis. 2013;13:26.
- [8] Morgenthaler NG, Struk J, Chancerelle Y, Weglöhner W, Agay D, Bohuon C, et al. Production of Procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res. 2003;35(5):290-95.
- [9] Zhang L, Ma L, Zhou X, Meng J, Wen J, Huang R, et al. Diagnostic value of procalcitonin for bacterial meningitis in children: A comparison analysis between serum and cerebrospinal fluid procalcitonin levels. Clin Pediatr (Phila). 2019;58(2):159-165.
- [10] White K, Ostrowski K, Maloney S, Norton R. The utility of cerebrospinal fluid parameters in the early microbiological assessment of meningitis. Diagn Microbiol Infect Dis. 2012;73(1):27-30.
- [11] Foushee JA, Hope NH, Grace EE. Applying biomarkers to clinical practice: A guide for utilizing procalcitonin assays. J Antimicrob Chemother. 2012;67(11):2560-69.
- [12] Schuetz P, Albrich W, Muller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: Past, present and future. BMC Med. 2011;9:107.
- [13] Shorbagy HH, Barseem NF, Abdelghani WE, Suliman HA, Al Shokary AH, Elsadek AE, et al. The value of serum procalcitonin in acute meningitis in children. J Clin Neurosci. 2018:56:28-33
- [14] Viallon A, Desseigne N, Marjollet O, Birynczyk A, Belin M, Guyomarch S, et al. Meningitis in adult patients with a negative direct cerebrospinal fluid examination: Value of cytochemical markers for differential diagnosis. Crit Care. 2011;15:(3)R136.
- [15] Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol. 2010;48(7):2325-29.
- [16] Mills GD, Lala HM, Oehley MR Craig AB, Barratt K, Hood D, et al. Elevated procalcitonin as a diagnostic marker in meningococcal disease. Eur J Clin M icrobiol Infect Dis. 2006;25(8):501-09.
- [17] Jereb M, Muzolvic I, Hojker S, Strle F. Predictive value of serum and cerebrospinal fluid procalcitonin levels for the diagnosis of bacterial meningitis. Infection. 2001;29(4):209-12.
- [18] Alkholi UM, Abd AN, Abd EAA, Sultan MH. Serum procalcitonin in viral and bacterial Meningitis. J Global Infect Dis. 2011;3(1):14-18.
- [19] Ahmad M, Ali S, Iqbal J, Wani F, Ahmad J. Cerebrospinal fluid procalcitonin: A promising diagnostic tool in differentiating bacterial from aseptic meningitis. Int J Contem Paediatrics 2019;6(5):1807-13.

- [20] Shimetani K, Shimetani M, Mori N. Levels of three inflammation markers, C-reactive protein, serum amyloid A protein and procalcitonin, in the serum and cerebrospinal fluid of patients with meningitis. Scand J Clin Lab Invest. 2001;61:567-74. Available from: https://doi.org/10.1080/003655101753218337.
- [21] Gendrel D, Raymond J, Assicot M, Moulin F, Iniguez JL, Lebon P, et al. Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis. 1997;24:1240-42.
- [22] Beek DV, Gans J, Spanjaard L, Weisfelt M, Reistma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004;351(18):1849-59.
- [23] Chaudhary S, Bhatta N, Lamsal M, Chaudhari R, Khanal B. Serum procalcitonin in bacterial & non-bacterial meningitis in children. BMC Paediatrics. 2018;18(1):342.
- [24] Wei T, Hu Z, Qin B, Ma N, Tang Q, Wang L, et al. Diagnostic accuracy of procalcitonin in bacterial meningitis versus nonbacterial meningitis: A systematic review and meta-analysis. Medicine (Baltimore). 2016;95(11):e3079.
- [25] Takahashi W, Nakada TA, Abe R, Tanaka K, Matsumura Y, Oda S. Usefulness of interleukin 6 levels in the cerebrospinal fluid for the diagnosis of bacterial meningitis. J Crit Care. 2014;29(4):693.e1-6.
- [26] Roos KL, Tyler KL. Acute Meningitis (Chapter 138). In Janeson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalo J. Harrisons Principles of Internal Medicine, 20th Edn. New York. McGrawHill Education. 2018; Pp. 1000-06.
- [27] Li W, Sun X, Yuan F, Gao Q, Ma Y, Jiang Y, et al. Diagnostic accuracy of cerebrospinal fluid procalcitonin in Bacterial meningitis patients with empiric Antibiotic pretreatment. J Clin Microbiol 2017;55(4):1193-204.
- [28] Marais S, Thwaites G, Schoeman JF, Torok ME, Misra UK, Prasad K, et al. Tuberculous meningitis: A uniform case definition for use in clinical research. Lancet Infect Dis. 2010;10(11):803-12.
- [29] Beek DV. Progress and challenges in bacterial meningitis. Lancet. 2012;380:1623-24. Available from: https://doi.org/10.1016/S0140-6736(12)61808-X.
- [30] Oordt-Speets AM, Bolijn R, Van Hoorn RC, Bhavsar A, Kyaw MH. Global etiology of bacterial meningitis: A systematic review and meta-analysis. PLoS One. 2018;13(6):e0198772.
- [31] Vikse J, Henry BM, Roy J, Ramakrishnan PK, Tomaszewski KA, Walocha JA. The role of serum procalcitonin in the diagnosis of bacterial meningitis in adults: A systematic review and meta-analysis. Int J Infec Dis. 2015;30:68-76.
- [32] Makoo ZB, Soltani HR, Hasani A, Makoo EB, Mashrabi O. Diagnostic value of serum and cerebrospinal fluid procalcitonin in differentiation of bacterial from aseptic meningitis. Am J Infect Dis. 2010;6:(4)93-97.
- [33] Julian-Jimenez A, Morales-Casado M. Usefulness of blood and cerebrospinal fluid laboratory testing to predict bacterial meningitis in the emergency department. Neurologia (Engl Ed). 2019;34(2):105-13.
- [34] Earnst A, Morgenthaler NG, Buerger K, Dodel R, Noelker C, Sommer N, et al. Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation. J Neuroimmunol. 2007;189(1-2):169-74.
- [35] Shen HY, Gao W, Cheng J, Zhao S, Sun Y, Han Z, et al. Direct comparison of the diagnostic accuracy between blood and cerebrospinal fluid procalcitonin levels in patients with meningitis. Clin Biochem. 2015;48(16-17):1079-82.
- [36] Saproo N, Singh R. Role of procalcitonin in viral and bacterial meningitis. Int J Adv Med 2021;8(7):947-51.
- [37] Konstantinidis T, Cassimos D, Gioka D, Tsigalou C, Parasidis T, Alexandropoulou I, et al. Can procalcitonin in cerebrospinal fluid be a diagnstic tool for meningitis. J Clin Lab Analy. 2015;29:169-74.
- [38] Li Y, Zhang G, Ma R, Du Y, Zhang L, Li F, et al. The diagnostic value of cerebrospinal fluids procalcitonin and lactate for the differential diagnosis of post-neurosurgical bacterial meningitis and assettic meningitis. Clin Biochem. 2015;48(1-2):50-54.
- [39] Kim H, Roh Y, Yoon S. Blood procalcitonin level as a diagnostic marker of pediatric Bacterial meningitis: A systematic review and meta-analysis. Diagnostics. 2021;11(5):846.

PARTICULARS OF CONTRIBUTORS:

- 1. Senior Resident, Department of Neurology, IMS and SUM Hospital, Bhubaneswar, Odisha, India.
- 2. Associate Professor, Department of Physiology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India.
- 3. Professor, Department of Biochemistry, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India
- 4. Professor, Department of Internal Medicine, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India.
- 5. Professor, Department of Internal Medicine, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Pradip Kumar Behera,

Flat No. B 202, Elegance Apartment, Kalara Hanga, PO KIIT, Dist. Khurda, Bhubaneswar-751024, Odisha, India.

E-mail: drpradip76@gmail.com

PLAGIARISM CHECKING METHODS: [Jain H et al.]

Plagiarism X-checker: Feb 03, 2024
 Manual Coording: Apr 03, 2024

Manual Googling: Apr 03, 2024iThenticate Software: Apr 13, 2024 (15%)

ETYMOLOGY: Author Origin

EMENDATIONS: 7

AUTHOR DECLARATION:

- Financial or Other Competing Interests: None
- Was Ethics Committee Approval obtained for this study?
 Yes
- Was informed consent obtained from the subjects involved in the study? Yes
- For any images presented appropriate consent has been obtained from the subjects.

Date of Submission: Feb 03, 2024 Date of Peer Review: Mar 01, 2024 Date of Acceptance: Apr 16, 2024 Date of Publishing: Jun 01, 2024